



# Medical Device Coordination Group

EUDAMED State of Play

*DG SANTE Unit R4, IT Systems*

*3 April, 2025*

# Agenda

- 1. Planned Releases**
- 2. Upcoming Development Priorities**
- 3. EUDAMED Audit update**
- 4. 2025 Key Focus areas**

# Planned Releases

PG 3.11.0 (mid-April)

## Content of the Release

### Actors & User Registration

- Bug Fixes & Useability improvements

### Devices Module

- Master UDI-DI registration process enhancements
- Public API
- Bug Fixes & Useability improvements

### NB & Certificates Module

- Bug Fixes & Useability improvements

### Market Surveillance Module

- Bug Fixes & Useability improvements

### Vigilance Module

- DTX Upload (Create and Update) & Download MIR, FSCA, FSN, NCAR
- DTX Download for MTR, PSUR
- Improved search functionality in application
- Bug Fixes & Useability improvements

## Feedback Period Timeline to be defined

nonDTX Functionalities and Public API possibly same as usual, around 4-5 weeks

Longer period for Vigilance DTX Functionalities

# Upcoming Development priorities

Next development priorities is a combination of functionalities coming from the prioritized list of Functional specifications (for mandatory use) and User feedback suggestions/ improvements received during the previous Playground Releases to ensure the best user experience using EUDAMED.

## Among others:

- ✓ M2M Upload functionality for Notified Bodies
- ✓ M2M Upload of Market Surveillance data from MS national databases
- ✓ Clinical Evaluation Consultation Procedure Outside of EUDAMED and Mechanism for Scrutiny inside of EUDAMED
- ✓ Authorized Representative receives notification when new Basic UDI-DI is submitted
- ✓ User Experience enhancement in Market Surveillance Module
- ✓ Certificate Notifications full implementation
- ✓ Versioning of EMDN and IMDRF Codes
- ✓ Initial certificate may have other status than Issued
- ✓ Mergers & Acquisitions

**& MANY more  
(analysis ongoing)**

# EUDAMED Audit update

\*The overall status of the Project  
– **GREEN**

In total more than 940 Test  
Cases created/ executed

*\*Source: Audit bi-weekly  
reporting meeting*

## Actor/ Devices/ Certificates

- Core test execution completed (pass rate above 98%)
- Regression testing for Actor completed; Certificates in Progress
- M2M testing completed except for NB
- **Next Steps:** API testing & M2M download for NB

## Market Surveillance

- Core testing and Regression testing completed
- M2M testing completed except for NB
- **Next Steps** – M2M download for NB

## Vigilance

- Initial Review of the module conducted

- The Review of Actor/ Devices/ Certificates/ MSU to be finalized by end of April with Final Audit Report to be published around May 2025
- The Audit for Vigilance will continue till October with Vigilance Audit report to be finalized possibly by end October/ November 2025

# 2025 Key Focus Areas

## First 4 Modules

- Fix all audit findings to finalize Minimum Viable Product (MVP)
- Additional Stabilization & Scalability of first 4 modules (including Security, Vulnerability and Performance testing)
- Initiate prioritized development of nonMVP but for Mandatory Use

## Vigilance

- Finalize MVP Development & implement recommendations from CA Vigilance Oversight Board (i.e. DTX/ M2M; Search and View)
- Fix all audit findings to finalize Minimum Viable Product
- Additional Stabilization & Scalability (including Security, Vulnerability and Performance testing)
- Initiate prioritized development of nonMVP but for Mandatory Use
- DTX WG took place on 6 March 2025

## Onboarding activities

- Technical documentation update and user guides revision ongoing
- Translation of User Guides planned and User interface translation started (with initially focus on first 4 modules to go live)
- Onboarding Workshops: **Stuttgart** May 2025, **Rome** October 2025, **Brussels** December 2025
- Medical devices related events reach out
- Call for expression of interest for train the trainer sent to CAs and Stakeholders
- Trainings (module and actor specific)

# 2025 Key Focus Areas

## First 4 Modules – Actor, Devices, Certificates, Market Surveillance

- Fix all audit findings to finalize Minimum Viable Product (MVP)
- Additional Stabilization & Scalability of first 4 modules (including Security, Vulnerability and Performance testing)
- Initiate prioritized development of nonMVP but for Mandatory Use

2025

2026

Q2

Q3

Q4

Q1

*Audit fixing*

*Vulnerability &  
Performance  
testing*

*Prioritized development of nonMVP but for Mandatory Use functionalities  
(i.e. M2M Upload for NBs)*

*Mandatory Use for  
Actor/Devices/ Certificates/  
MSU*

# 2025 Key Focus Areas

## First 4 Modules – Actor, Devices, Certificates, Market Surveillance

### Onboarding activities

- Technical documentation update and user guides revision ongoing
- Translation of User Guides planned and User interface translation started (with initially focus on first 4 modules to go live)
- Onboarding Workshops: **Stuttgart** May 2025, **Rome** October 2025, **Brussels** December 2025
- Medical devices related events reach out
- Call for expression of interest for train the trainer sent to CAs and Stakeholders
- Trainings (module and actor specific)

2025

2026

Q2

Q3

Q4

Q1

*Audit fixing*

*Stuttgart*

*Rome*

*Brussels*

*Vulnerability & Performance testing*

*Improvements & Translation of User Guides  
Relevant Technical Docs Updates*

*Prioritized development of nonMVP but for Mandatory Use Scope  
(i.e. M2M Upload for NBs)*

*Mandatory Use for  
Actor/Devices/ Certificates/  
MSU*


# 2025 Key Focus Areas

## Vigilance

- Finalize MVP Development & implement recommendations from CA Vigilance Oversight Board (i.e. DTX/ M2M; Search and View)
- Fix all audit findings to finalize Minimum Viable Product
- Additional Stabilization & Scalability (including Security, Vulnerability and Performance testing)
- Initiate prioritized development of nonMVP but for Mandatory Use
- DTX WG took place on 6 March 2025

# Current planning for gradual roll out and modules' functionality view

◆ Face-to-Face events in specific locations





# Thank you – Questions?

## Keep in Touch

EUDAMED Support email address: [SANTE-EUDAMED-SUPPORT@ec.europa.eu](mailto:SANTE-EUDAMED-SUPPORT@ec.europa.eu)

[EUDAMED Information Centre on Production](#)

# EUDAMED Production Statistics



# EUDAMED High Level Timeline

## DTX MIR Implementation

